Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 5/2018

01-05-2018 | Letter to the Editor

Infections associated with ruxolitinib: study in the French Pharmacovigilance database

Authors: Pinel Sylvine, Sternjacob Thomas, Eftekhari Pirayeh, The French Network of Regional Pharmacovigilance Centers

Published in: Annals of Hematology | Issue 5/2018

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Yang LPH, Keating KM (2012) Ruxolitinib: In the Treatment of Myelofibrosis. Drugs 72 (16):2117–2127
2.
Saeed I, McLornan D, Harrison CN (2017) Managing side effects of JAK inhibitors for myelofibrosis in clinical practice. Expert Rev Hematol 10(7):617–625
3.
Abidi MZ, Haque J, Varma P and al (2016) Reactivation of pulmonary tuberculosis following treatment of myelofibrosis with ruxolitinib. Case Rep Hematol Article ID 2389038
4.
Malkan UY, Haznedaroglu IC (2017) A myelofibrosis case that develops mycobacterial infection after ruxolitinib treatment (case report). Int J Clin Exp Med 10(4):7304–7307
5.
Pálmason R, Lindén O, Richter J (2015) EBV driven lymphoproliferative disorder associated with ruxolitinib (case-report). BMC Hematol 15:10
6.
Cen CC, Chen YY, Huang CE (2016) Cryptococcal meningoencephalitis associated with the long-term use of ruxolitinib. Ann Hematol 95:361–362
7.
Kusano Y, Terui Y, Ueda K and al (2016) Klebsiella pneumoniae primary liver abscess associated withruxolitinib Ann Hematol 95:1561–1562
8.
Shen CH, Hwang CE, Chen YY and al (2014) Hepatitis B virus reactivation associated with ruxolitinib. Ann Hematol 93:1075–1076
9.
Manduzio P (2017) Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor. Ther Clin Risk Manag 13:169–177
10.
Schönberg K, Rudolph J, Vonnahme M and al (2015) JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms. Cancer Res 75(11):2187–2199
Metadata
Title
Infections associated with ruxolitinib: study in the French Pharmacovigilance database
Authors
Pinel Sylvine
Sternjacob Thomas
Eftekhari Pirayeh
The French Network of Regional Pharmacovigilance Centers
Publication date
01-05-2018
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 5/2018
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-018-3242-8

Other articles of this Issue 5/2018

Annals of Hematology 5/2018 Go to the issue

Original Article

The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma

Letter to the Editor

Sequential development of monoclonal B cell lymphocytosis-derived small lymphocytic lymphoma and plasma cell leukemia

Letter to the Editor

Serious concerns on the inability of FDG-PET in excluding residual viable lymphoma

Original Article

Risk of adverse events associated with front-line anti-myeloma treatment in Medicare patients with multiple myeloma

Original Article

Cecum ulcer is a reliable endoscopic finding in cytomegalovirus colitis concomitant with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Review Article

Sleep-disordered breathing in patients with sickle cell disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits